• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Reply to: "Assessment of hepatic fibrosis in MAFLD: a new player in the evaluation of residual cardiovascular risk?".

作者信息

Zelber-Sagi Shira, Schonmann Yochai, Yeshua Hanny, Bentov Itay

机构信息

School of Public Health, University of Haifa, 3498838 Haifa, Israel; Liver Unit, Department of Gastroenterology, Tel-Aviv Medical Center, 6423906 Tel-Aviv, Israel.

Siaal Research Center for Family Medicine and Primary Care, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel; Department of Quality Measurements and Research, Clalit Health Services, Tel Aviv, Israel.

出版信息

Dig Liver Dis. 2021 Mar;53(3):385-386. doi: 10.1016/j.dld.2021.01.014. Epub 2021 Jan 25.

DOI:10.1016/j.dld.2021.01.014
PMID:33509738
Abstract
摘要

相似文献

1
Reply to: "Assessment of hepatic fibrosis in MAFLD: a new player in the evaluation of residual cardiovascular risk?".回复：“非酒精性脂肪性肝病中肝纤维化的评估：评估残余心血管风险的新要素？”
Dig Liver Dis. 2021 Mar;53(3):385-386. doi: 10.1016/j.dld.2021.01.014. Epub 2021 Jan 25.
2
Assessment of hepatic fibrosis in MAFLD: A new player in the evaluation of residual cardiovascular risk?非酒精性脂肪性肝病（MAFLD）中肝纤维化的评估：评估残余心血管风险的新要素？
Dig Liver Dis. 2021 Mar;53(3):383-384. doi: 10.1016/j.dld.2020.12.123. Epub 2021 Jan 20.
3
Advanced fibrosis is associated with incident cardiovascular disease in patients with non-alcoholic fatty liver disease.晚期肝纤维化与非酒精性脂肪性肝病患者心血管疾病的发生有关。
Aliment Pharmacol Ther. 2020 Apr;51(7):728-736. doi: 10.1111/apt.15660. Epub 2020 Feb 11.
4
Advanced fibrosis of non-alcoholic steatohepatitis affects the significance of lipoprotein(a) as a cardiovascular risk factor.非酒精性脂肪性肝炎的晚期纤维化影响脂蛋白(a)作为心血管危险因素的重要性。
Atherosclerosis. 2020 Apr;299:32-37. doi: 10.1016/j.atherosclerosis.2020.02.026. Epub 2020 Mar 7.
5
MAFLD identifies patients with significant hepatic fibrosis better than NAFLD.与非酒精性脂肪性肝病（NAFLD）相比，代谢功能障碍相关脂肪性肝病（MAFLD）能更好地识别出有显著肝纤维化的患者。
Liver Int. 2020 Dec;40(12):3018-3030. doi: 10.1111/liv.14675.
6
Evaluation of Cardiovascular Risk in Patient with Primary Non-alcoholic Fatty Liver Disease.原发性非酒精性脂肪性肝病患者心血管风险评估
High Blood Press Cardiovasc Prev. 2020 Aug;27(4):321-330. doi: 10.1007/s40292-020-00389-8. Epub 2020 May 20.
7
Editorial: liver stiffness by magnetic resonance elastography and cardiovascular risk in non-alcoholic fatty liver disease-simply associated or more complicated? Authors' reply.社论：磁共振弹性成像检测的肝脏硬度与非酒精性脂肪性肝病中的心血管风险——仅仅是相关还是更为复杂？作者回复
Aliment Pharmacol Ther. 2021 Jun;53(11):1230-1231. doi: 10.1111/apt.16364.
8
NAFLD and Cardiometabolic Risk Factors: The Liver Fibrosis Trajectory Through the Lens of Biological Interactions.非酒精性脂肪性肝病与心血管代谢危险因素：透过生物相互作用视角看肝纤维化进程
Hepatology. 2021 Feb;73(2):479-482. doi: 10.1002/hep.31672.
9
Prescription of statins in suspected non-alcoholic fatty liver disease and high cardiovascular risk, a population-based study.在疑似非酒精性脂肪性肝病和高心血管风险患者中开具他汀类药物处方：一项基于人群的研究。
Liver Int. 2019 Jul;39(7):1343-1354. doi: 10.1111/liv.14116. Epub 2019 Jun 10.
10
Both alcoholic and non-alcoholic steatohepatitis association with cardiovascular risk and liver fibrosis.酒精性和非酒精性脂肪性肝炎均与心血管风险和肝纤维化相关。
Alcohol. 2018 Jun;69:63-67. doi: 10.1016/j.alcohol.2017.11.004. Epub 2017 Nov 15.

引用本文的文献

1
An international multidisciplinary consensus statement on MAFLD and the risk of CVD.国际多学科共识声明：MAFLD 和 CVD 风险。
Hepatol Int. 2023 Aug;17(4):773-791. doi: 10.1007/s12072-023-10543-8. Epub 2023 May 19.